Glaxo Smithkline Pharmaceutical Ltd. Through Its Senior General Manager Legal and Secretarial v. Union of India
In short. The case involves Glaxo SmithKline Pharmaceuticals Ltd. (the appellant) appealing against the Union of India (the respondent) regarding the interpretation of paragraph 28 of the Drugs (Prices Control) Order, 1987 (DPCO). The core issue was whether the appellant was entitled to continue charging prices for Betamethasone Disodium Phosphate beyond the exemption period granted by the government. The Supreme Court ruled in favor of the Union of India, affirming that the appellant had violated the price control provisions after the exemption period expired, leading to a liability of Rs. 1.90 crores for overcharging.
Facts
The case arose from a notification issued on February 28, 1992, which exempted Glaxo India Ltd. from price control for Betamethasone Disodium Phosphate until December 31, 1994. Following the expiration of this exemption, the government issued a show cause notice on June 10, 1997, indicating that the appellant had continued to charge prices above the government-fixed rates, resulting in a significant overcharge. The appellant contended that they had applied for a fresh cost study prior to the expiration of the exemption, which they believed justified their pricing.
Arguments
Petitioner Arguments
The appellant argued that
- They had submitted an application for a fresh cost study before the exemption period ended, which should allow them to set their own prices.
- The government’s fixed price was not applicable as they were in the process of seeking a new price determination.
The court addressed these arguments by emphasizing that the mere submission of an application for a cost study did not grant the appellant the right to charge prices independently of the government-fixed prices once the exemption period had lapsed.
Respondent Arguments
The respondent contended that
- The exemption was strictly time-bound, and once it expired, the appellant was required to adhere to the government-fixed prices.
- The appellant's continued pricing above the fixed rates constituted a violation of the DPCO provisions.
The court supported the respondent's position, highlighting the clear stipulations in the DPCO regarding the expiration of exemptions and the obligation to comply with price controls thereafter.
Precedents considered
The judgment did not explicitly cite prior case law but relied on the interpretation of the DPCO and the principles of administrative law regarding the enforcement of price controls. The court's reasoning was grounded in the statutory framework established by the DPCO.
Legal principles
The court considered several legal principles, including
- The binding nature of government notifications regarding price controls.
- The requirement for compliance with price regulations post-exemption.
- The significance of timely applications for price adjustments and their implications on pricing authority.
Decision and reasoning
Rationale
The court reasoned that the DPCO's provisions were designed to protect public interest by regulating drug prices. The appellant's failure to comply with the fixed prices after the exemption period indicated a disregard for these regulations. The court criticized the appellant's reliance on the pending application for a cost study as insufficient to justify their pricing practices.
Outcome
The Supreme Court upheld the decision of the lower authorities, confirming that Glaxo SmithKline Pharmaceuticals Ltd. was liable for overcharging and ordered the recovery of Rs. 1.90 crores. The court did not provide specific instructions for an appeal process, as the ruling was final.
Conclusion
This judgment reinforces the importance of compliance with statutory price controls in the pharmaceutical industry, emphasizing that exemptions are strictly regulated and time-bound. It serves as a precedent for future cases involving price control violations, highlighting the necessity for manufacturers to adhere to government regulations post-exemption.
Read the full judgment on the Supreme Court website (PDF)
Find the judgments that followed or distinguished it, with the paragraph relied on in each. Two answers free on WhatsApp, no signup.